Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DBVT with free AI briefings, catalyst countdowns, and dilution alerts.

DBVT · DBV Technologies S.A.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$165.7M Cash on Hand
9.6mo Cash Runway
Follow DBVT by email Get an email when DBVT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DBVT, unsubscribe in one click. Privacy

📣 What DBVT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

DBVT holds $165.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $52.1M/quarter from operations, an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DBVT files for a raise →

👥 Who Owns DBVT

Insiders 6% Other 5%+ holders 7.9% Institutions (76 holders) 39% Public and other holders 47.1%
HolderTypeShares% of sharesAs of
Baker Bros. Advisors LP Institution (13G, 5%+) 25,586,190 8.14% 2026-01-12
Raymond Debbane 5%+ holder (13G) 24,716,176 7.86% 2026-09-30
Adage Capital Management, L.P. Institution (13G, 5%+) 22,272,884 7.08% 2026-03-31
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 20,469,392 6.51% 2025-12-31
RA Capital Management, L.P. Institution (13G, 5%+) 18,288,220 5.82% 2026-07-30
Bpifrance SA
10% owner
Insider 10,898,595 3.47% 2025-03-27
Bpifrance EPIC
Member of 10% owner group
Insider 7,529,502 2.39% 2025-12-17
Investissement S.A.S. Bpifrance
Member of 10% owner group
Insider 226,133 0.07% 2025-03-27
Pharis Mohideen
Chief Medical Officer · +683,000 options
Insider 144,531 0.05% 2026-07-29
Virginie Boucinha
Chief Financial Officer · +418,000 options
Insider 70,000 0.02% 2025-11-21
Kevin Michael Trapp
Chief Commercial Officer · +316,250 options
Insider 55,000 0.02% 2025-11-21
Daniel Tasse
CHIEF EXECUTIVE OFFICER, Director · +2.58M options
Insider 17,094 0.01% 2024-03-08

Share count 314,388,807 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full DBVT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DBVT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.